Summary & Overview
HCPCS J9317: Sacituzumab Govitecan-hziy Injection, 2.5 mg
HCPCS Level II code J9317 denotes administration of sacituzumab govitecan-hziy in 2.5 mg units, an antibody-drug conjugate used in oncology. As a drug-specific HCPCS code, J9317 matters for accurate billing, inventory management, and reimbursement for infusion-based cancer care across outpatient settings. Nationally, biologic and specialty drug coding influences provider revenue cycles, prior authorization workflows, and payer coverage determinations.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context, expected sites of service, and the payer landscape. The publication outlines benchmarks and payment policy considerations relevant to specialty oncology drugs, highlights common billing practices tied to unit-based HCPCS drug reporting, and summarizes any recent administrative guidance or coding clarifications when available. Where input data is limited, the report flags missing details for clarity.
This summary equips revenue cycle managers, oncology billing staff, practice administrators, and policy analysts with the essential information needed to align coding, billing, and authorization processes for infusions of J9317 without prescribing clinical or operational actions.
Billing Code Overview
HCPCS Level II code J9317 represents the drug sacituzumab govitecan-hziy, billed per unit of 2.5 mg for intravenous injection. This code is used to report administration of the specified oncologic antibody-drug conjugate.
Service Type: Drug administration (intravenous anticancer therapy)
Typical Site of Service: Hospital outpatient infusion center, specialty oncology clinic, or ambulatory infusion center
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with metastatic triple-negative breast cancer or another FDA‑approved indication for sacituzumab govitecan-hziy who presents to an oncology infusion center for intravenous administration. The oncology team verifies recent laboratory results (complete blood count, hepatic and renal function), confirms current medications and allergies, reviews prior lines of therapy and treatment response, and completes chemotherapy consent and premedication orders. The pharmacist compounds the dose in an appropriate sterile environment based on weight or body surface area and the drug vial strength (J9317 billed per 2.5 mg). The infusion nurse performs baseline vital signs, obtains venous access (peripheral IV or implanted port), administers premedications (antiemetic and antipyretic as indicated), and infuses the drug per institutional protocol with monitoring for infusion reactions. Post‑infusion assessment documents tolerance and any adverse effects; orders for growth factor support, antiemetics, or dose modifications are placed as needed. Billing uses J9317 with appropriate modifiers to indicate circumstances such as inpatient vs outpatient, partial administration, or discontinuation.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW |